Poland· PL-100488138
Inaqovi
A decitabin, kombinationen product containing decitabinum + cedazuridinum, registered in Poland by Otsuka Pharmaceutical Netherlands B.V.. The same ATC class is registered in 10 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Decitabin, kombinationen is registered in 10 of 19 countries.
Countries holding a registration under ATC L01BC58 (decitabin, kombinationen), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Decitabin, kombinationen · ATC L01BC58
10 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
The record
At a glance
URPL (Poland)- Active substance
- Decitabinum + Cedazuridinum
- Manufacturer
- Otsuka Pharmaceutical Netherlands B.V.
- Country
- Poland (PL)
- ATC code
- L01BC58
- ATC class
- Decitabin, Kombinationen
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Decitabin, kombinationen in 11 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CzechiaINAQOVIOtsuka Pharmaceutical Netherlands B.V., Amsterdam
- United StatesINQOVITaiho Pharmaceutical Co., Ltd.
- CanadaINQOVITAIHO PHARMA CANADA, INC.
- SpainINAQOVI 35 MG/100 MG COMPRIMIDOS RECUBIERTOS CON PELICULAOtsuka Pharmaceutical Netherlands B.V.
- FinlandInaqoviOtsuka Pharmaceutical Netherlands B.V.
- United KingdomInaqovi 35mg/100mg tabletsOtsuka Pharmaceuticals (U.K.) Ltd
- IrelandInaqovi 35 mg/100 mg film-coated tabletsOtsuka Pharmaceutical Netherlands B.V.
- IcelandInaqoviOtsuka Pharmaceutical Netherlands B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Inaqovi
- Liechtenstein · Inaqovi
- Norway · Inaqovi
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/6bce2c88-e7c1-4c2e-bb2c-0c141b196937 GET /v1/drugs/6bce2c88-e7c1-4c2e-bb2c-0c141b196937?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "35 mg + 100 mg",
"packaging": "Rpz ¦ EU/1/23/1756/001 ¦ 151552\n5 tabl.",
"substance": "Decitabinum 35 mg + Cedazuridinum 100 mg",
"common_name": "Decitabinum + Cedazuridinum",
"pl_product_id": "100488138",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about decitabin, kombinationen.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.